for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Intrexon Corp

XON.N

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
21.41
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
162.51
Market Cap (MIL)
873.61
Forward P/E
-4.25
Dividend (Yield %)
--

Next Event

Q4 2019 Intrexon Corp Earnings Release

Latest Developments

More

Intrexon Reports Q3 Revenue Of $23 Mln

Intrexon Says Q2 Revenue $36 Million

Intrexon Corporation And Surterra Wellness Partner In $100 Mln Deal To Advance Commercial Scale Fermentation-Based Cannabinoid Production

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Intrexon Corp

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Industry

Biotechnology & Drugs

Contact Info

1750 Kraft Dr Ste 1400

+1.301.5569809

https://www.dna.com/

Executive Leadership

Randal J. Kirk

Chairman of the Board, Chief Executive Officer

Thomas D. Reed

Founder, Chief Science Officer

Rick L. Sterling

Chief Financial Officer

Helen Sabzevari

President of Precigen, Inc.

Thomas Bostick

Chief Operating Officer

Key Stats

3.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.2K

2018

0.2K

2019(E)

0.1K
EPS (USD)

2016

-1.580

2017

-0.840

2018

-3.930

2019(E)

-1.265
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.96
Price To Book (MRQ)
3.82
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
94.58
LT Debt To Equity (MRQ)
80.57
Return on Investment (TTM)
-71.17
Return on Equity (TTM)
-62.63

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up